Abstract
Bacillus anthracis, the causative agent responsible for anthrax infections, poses a significant biodefense threat. There is a high mortality rate associated with untreated anthrax infections; specifically, inhalation anthrax is a particularly virulent form of infection with mortality rates close to 100%, even with aggressive treatment. Currently, a vaccine is not available to the general public and few antibiotics have been approved by the FDA for the treatment of inhalation anthrax. With the threat of natural or engineered bacterial resistance to antibiotics and the limited population for whom the current drugs are approved, there is a clear need for more effective treatments against this deadly infection. A comprehensive review of current research in drug discovery is presented in this article, including efforts to improve the purity and stability of vaccines, design inhibitors targeting the anthrax toxins, and identify inhibitors of novel enzyme targets. High resolution structural information for the anthrax toxins and several essential metabolic enzymes has played a significant role in aiding the structure-based design of potent and selective antibiotics.
Keywords: Biodefense, anthrax toxins, antibiotics, structure-based drug design, vaccines, B. anthracis, inhalation anthrax, resistance, lethal factor, edema factor
Current Medicinal Chemistry
Title: New Developments in Vaccines, Inhibitors of Anthrax Toxins, and Antibiotic Therapeutics for Bacillus anthracis
Volume: 18 Issue: 33
Author(s): J. M. Beierlein and A. C. Anderson
Affiliation:
Keywords: Biodefense, anthrax toxins, antibiotics, structure-based drug design, vaccines, B. anthracis, inhalation anthrax, resistance, lethal factor, edema factor
Abstract: Bacillus anthracis, the causative agent responsible for anthrax infections, poses a significant biodefense threat. There is a high mortality rate associated with untreated anthrax infections; specifically, inhalation anthrax is a particularly virulent form of infection with mortality rates close to 100%, even with aggressive treatment. Currently, a vaccine is not available to the general public and few antibiotics have been approved by the FDA for the treatment of inhalation anthrax. With the threat of natural or engineered bacterial resistance to antibiotics and the limited population for whom the current drugs are approved, there is a clear need for more effective treatments against this deadly infection. A comprehensive review of current research in drug discovery is presented in this article, including efforts to improve the purity and stability of vaccines, design inhibitors targeting the anthrax toxins, and identify inhibitors of novel enzyme targets. High resolution structural information for the anthrax toxins and several essential metabolic enzymes has played a significant role in aiding the structure-based design of potent and selective antibiotics.
Export Options
About this article
Cite this article as:
M. Beierlein J. and C. Anderson A., New Developments in Vaccines, Inhibitors of Anthrax Toxins, and Antibiotic Therapeutics for Bacillus anthracis, Current Medicinal Chemistry 2011; 18 (33) . https://dx.doi.org/10.2174/092986711797636036
DOI https://dx.doi.org/10.2174/092986711797636036 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Turning Up the Pressure on Vascular Disease
Current Neurovascular Research “Connecting the Dots” from Blood Brain Barrier Dysfunction to Neuroinflammation and Alzheimer’s Disease
Current Neurovascular Research Impact of Antiretroviral Therapy on the Relapse of Cryptococcosis and Survival of HIV-Infected Patients with Cryptococcal Infection
Current HIV Research Drug Discovery in Enteroviral Infections
Infectious Disorders - Drug Targets The Role of Toll-Like Receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A New Promising Therapeutic Approach?
CNS & Neurological Disorders - Drug Targets In-silico Subtractive Proteomic Analysis Approach for Therapeutic Targets in MDR Salmonella enterica subsp. enterica serovar Typhi str. CT18
Current Topics in Medicinal Chemistry Classical Neurotransmitters and Neuropeptides Involved in Parkinson's Disease: Focus on Anti-Parkinsonian Drugs
Current Drug Therapy The Efficacy of Viral Capsid Inhibitors in Human Enterovirus Infection and Associated Diseases
Current Medicinal Chemistry A Critical Analysis of New Molecular Targets and Strategies for Drug Developments in Alzheimers Disease
Current Drug Targets Special Features of Gram-Positive Bacterial Eradication by Photosensitizers
Recent Patents on Anti-Infective Drug Discovery subject Index To Volume 1
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Role of Bacterial Lipopolysaccharides as Immune Modulator in Vaccine and Drug Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Characterization and antiherpetic activity of native and chemically sulfated polysaccharide from <i>Adenanthera pavonina</i>
Current Pharmaceutical Biotechnology Magnetite Nanoshuttles for Fighting Staphylococcus aureus Infections: A Recent Review
Current Topics in Medicinal Chemistry Childhood Systemic Lupus Erythematosus: New and Old Treatments
Current Pediatric Reviews Neurotrophic Factors in the Pathogenesis of Neurological Disorders with Mental Retardation in Children
Current Pediatric Reviews Intravenous Immunoglobulins for Alzheimer's Disease
Current Alzheimer Research Intravenous Immunoglobulin Preparations and Autoimmune Disorders: Mechanisms of Action
Current Pharmaceutical Biotechnology Seroprevalence of Hepatitis E Virus Infection Among Pregnant Women in Ilam, West of Iran
Infectious Disorders - Drug Targets Ceftriaxone-Vancomycin Drug Toxicity Reduction by VRP 1020 in Mus musculus Mice
Current Clinical Pharmacology